|
|
 |
September 30, 2008 |
Now Available:
Watch video podcasts of the 2008 EULAR press conferences
CME Meetings:
MSK Report provides cutting-edge scientific updates through biweekly and special edition newsletters, in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts, making it the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
Online CME Opportunity:
Arthritis: Pegloticase May be Just What the Rheumatologist Ordered for Treatment-Resistant Gout
Treatment-resistant gout may have finally met its match with a new, urate-lowering drug...
Bones: ASBMR Reports Show 68% Drop in Spinal Fractures With Denosumab, Stronger Effect on Bone Turnover Than With Alendronate, High Patient Preference
Studies reported at the 2008 ASBMR meeting showed that denosumab, which is given twice yearly, was as effective as the best competing agents at preventing osteoporotic fractures. Denosumab produced greater gains in BMD than alendronate and was preferred to once-weekly oral alendronate...
Autoimmunity: Microparticles May Be Big Players in Systemic Scleroderma Disease Activity
Microparticles—small, membrane, coated vesicles—found in the blood of systemic scleroderma patients might not be inert debris...
Consumer News: Microscopic Version of the CT Scan Reveals Secrets of Bone Formation
A new version of the CT scan offers insight on how bones, shells, and other animal structures are formed, which may give researchers a better understanding of bone loss and how to combat it...
BioPharm Business: Abbott Reports Continuous Treatment With Humira Achieves Superior Long-Term Efficacy for Psoriasis Patients in the US and Europe Versus Interrupting Treatment
The findings were from the company's pivotal 52-week REVEAL study and the period of open-label treatment that followed...